Beijing: Innovative drugs in commercial insurance are not subject to the "one product, two regulations" restrictions, exploring supply guarantees through the "dual-channel" mechanism in designated medical institutions or contracted pharmacies.

The Beijing Municipal Medical Security Administration and other departments issued the "Several Measures to Support the High-Quality Development of Commercial Health Insurance in Beijing," which proposes supporting the clinical application of innovative drugs and medical devices. Support will be provided for innovative drugs under commercial insurance to be quickly included in the network through a green channel, without being included in the basic medical insurance self-payment rate index and the monitoring range of selected alternative varieties in centralized procurement. Medical institutions shall not affect the use of innovative drugs under commercial insurance by citing the number of drugs in the medical institution's drug list or the proportion of drugs. Innovative drugs under commercial insurance may not be subject to the restrictions of the "one-drug, two-rule" policy, and the guarantee of supply may be explored through a "dual-channel" mechanism at designated medical institutions or agreement drugstores. The expenses for new drugs and new technologies that meet the criteria will not be included in the DRG group payment standards, and will be paid separately; the application cases of innovative drugs under commercial insurance may not be included in the scope of medical insurance payment by disease group, and will be paid after the review and evaluation process.